A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

被引：0
|
作者：
Kang, Hyunseok
Ahn, Myung-Ju
Muzaffar, Jameel
Keam, Bhumsuk
Bowles, Daniel W.
Wong, Deborah J. L.
Ho, Alan Loh
Kim, Sung-Bae
Worden, Francis P.
Yun, Tak
Sari, Suha
Conlan, Maureen G.
Hanna, Glenn J.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Hematol Oncol, San Francisco, CA USA
[2] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] H Lee Moffitt Canc Ctr & Res Inst, Head & Neck & Endocrine Oncol, Tampa, FL USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Univ Colorado Canc Ctr, Div Med Oncol, Aurora, CO USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, Div Solid Tumor Oncol, New York, NY USA
[8] Univ Ulsan Coll Med, Asan Med Ctr, Seoul, South Korea
[9] Univ Michigan, Rogel Canc Ctr, Endocrine Oncol Clin, Ann Arbor, MI USA
[10] Natl Canc Ctr, Ctr Specif Organs Canc, Rare Cancers Clin, Goyang Si, Gyeonggi Do, South Korea
[11] Elevar Therapeut, Salt Lake City, UT USA
[12] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6020
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
    Kang, Hyunseok
    Ahn, Myung-Ju
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J. L.
    Ho, Alan Loh
    Kim, Sung-Bae
    Worden, Francis P.
    Jang, Tak Yun Seong
    Meng, Xianzhang
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
    Hanna, Glenn J.
    Ahn, Myung-Ju
    Muzaffar, Jameel
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J.
    Ho, Alan L.
    Kim, Sung-Bae
    Worden, Francis
    Yun, Tak
    Meng, Xianzhang
    Van Tornout, Jan M.
    Conlan, Maureen G.
    Kang, Hyunseok
    CLINICAL CANCER RESEARCH, 2023, 29 (22) : 4555 - 4563
  • [3] Efficacy and Tolerability of Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFRi) for Recurrent/ Metastatic Adenoid Cystic Carcinoma (R/M ACC): a Systematic Review and Meta-Analysis
    Hoff, C. O.
    Manzi, J.
    Lazar Neto, F.
    Ferrarotto, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E80 - E80
  • [4] Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor
    Nguyen, Jennifer P.
    Frost, Chelsea D.
    Lane, Meghan L.
    Skelton, William P.
    Skelton, Michelle
    Vesely, David L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 (10) : 1061 - 1067
  • [5] Endomucin regulates vascular endothelial growth factor (VEGF) Receptor 2 (VEGFR2) Endocytosis
    LeBlanc, M.
    Hu, Z.
    Saez-Torres, K.
    Saint-Geniez, M.
    Ng, E.
    D'Amore, P.
    AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (10) : 2420 - 2421
  • [6] Vascular endothelial growth factor receptor-2 (VEGFR2): structure and functional relationship
    Nathan, Jhansi Rani
    Shika, Shilpi
    Ragunathan, Malathi
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2013, 31 : 119 - 119
  • [7] Phase 2 Study of Apatinib, A Novel VEGFR Inhibitor in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: Preliminary Results
    Dou, S.
    Zhang, L.
    Li, R.
    Zhu, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1378 - 1379
  • [8] Endomucin Interacts with Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Regulates Its Activities
    Hu, Z.
    Leblanc, M.
    Saez-Torres, K.
    Saint-Geniez, M.
    Ng, E.
    D'Amore, P.
    AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (10) : 2420 - 2420
  • [9] Specific Role of Endomucin in Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Internalization and Function
    Hu, Zhengping
    Cano, Issahy
    Saint-Geniez, Magali
    Ng, Eric
    D'Amore, Patricia A.
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (10 S) : S6 - S6
  • [10] A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).
    Ferrarotto, Renata
    Bell, Diana
    Feng, Lei
    Li, Kaiyi
    Mott, Frank
    Blumenschein, George R.
    De Sousa, Luana Guimaraes
    Altan, Mehmet
    Marques-Piubelli, Mario L.
    Dal Lago, Eduardo Andreazza
    Kaya, Diana
    Godoy, Myrna
    Kupferman, Michael Elliot
    Glisson, Bonnie S.
    El-Naggar, Adel K.
    Elamin, Yasir Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345